Ephrin Signaling Modulation Therapy refers to therapeutic approaches that target the Ephrin/Eph receptor tyrosine kinase signaling system to treat neurodegenerative . The Ephrin-Eph system is the largest family of receptor tyrosine kinases and plays critical roles in synaptic plasticity, axon guidance, and neural circuit formation[1].
The Ephrin family consists of two subclasses:
The Eph receptors (EphA1-8, EphB1-6) are receptor tyrosine kinases that bind to their preferred ephrin ligands with high affinity[2].
One unique feature of Ephrin-Eph signaling is bidirectional signaling:
This bidirectional communication allows complex cell-cell interactions critical for synaptic function[3].
| Target | Therapeutic Approach | Disease Focus |
|---|---|---|
| EphA2 | Antagonist | Alzheimer's Disease |
| EphA4 | Antagonist | ALS, Stroke |
| EphB1 | Agonist | Alzheimer's Disease |
| Ephrin-A5 | Agonist | Alzheimer's Disease |
| Ephrin-B2 | Agonist | Parkinson's Disease |
Ephrin-Eph signaling plays a crucial role in regulating synaptic plasticity, the cellular basis of learning and memory. Studies have shown that:
Research has identified links between Ephrin-Eph signaling and Alzheimer's disease pathology:
The Ephrin-Eph system influences dopaminergic neuron development and survival:
Emerging evidence suggests Ephrin-Eph signaling may interact with alpha-synuclein pathology in Parkinson's disease:
Ephrin-Eph signaling is critical for axon guidance and neuromuscular junction (NMJ) formation:
As of 2024, no Ephrin signaling modulators have been approved for neurodegenerative . However, several programs are in preclinical development:
| Company/Institution | Compound | Target | Development Stage |
|---|---|---|---|
| Various academic labs | EphA4 antagonists | EphA4 | Preclinical (ALS) |
| Research labs | EphB1 agonists | EphB1 | Preclinical (AD) |
| Biotech startups | Ephrin-A5 agonists | EphA receptors | Discovery |
Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008. ↩︎
Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002. ↩︎
Murai KK, Pasquale EB. 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci. 2003. ↩︎
Klein R. Eph/ephrin signaling in brain development and function. Neuroscientist. 2009. ↩︎
Chen J, et al. EphA2 promotes beta-amyloid-induced tau pathology and cognitive deficits. Nat Neurosci. 2022. ↩︎
Yue Y, et al. Ephrin-B2 and EphB2 signaling in Parkinson's disease. Mol Neurobiol. 2021. ↩︎
Goldshmit Y, et al. EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury. Brain. 2014. ↩︎